Pardes Biosciences announced that MediPacific, an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, has successfully completed the previously announced tender offer to acquire all of Pardes’ outstanding shares of common stock for a per share price of $2.13 in cash, plus a non-tradeable contingent value right associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRDS:
- Pardes Biosciences Announces Closing of Tender Offer
- PRDS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pardes downgraded to Market Perform from Outperform at JMP Securities
- Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights
- MediPacific to acquire Pardes Biosciences for $2.02-$2.19 per share in cash
